ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 205 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  M3[zfWNmdGxiVnnhZoltcXS7IFHzd4F6 NUnVfoF[OjVyIH7NxsA> MUC3NkBp NY\GXWVsTE2VTx?= Mke3Z4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> M2LLTlI3PjV5Mki4
KG1a M2P5WGNmdGxiVnnhZoltcXS7IFHzd4F6 MkfyNE0yOCEQvF2= NU\XeFBSOjRiaB?= MmLxSG1UVw>? NGPMc4hKSzVyPUeuOlgh|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4G3[|I3PTV{N{Gy
Kasumi-1 MlrUR4VtdCCYaXHibYxqfHliQYPzZZk> M4nGRVAuOTBizszN NWHsWllNOjRiaB?= MoXmSG1UVw>? M2LEVGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHu3doYzPjV3MkexNi=>
KG1a MYTBdI9xfG:|aYOgRZN{[Xl? MYWwMVExKM7:TR?= NGL5b3IzPCCq Mlq2SG1UVw>? MX\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVKyOlU2OjdzMh?=
Kasumi-1 NEHGVZJCeG:ydH;zbZMhSXO|YYm= MnTsNE0yOCEQvF2= MnnCNlQhcA>? MlvISG1UVw>? NFfoSJFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkixNlY2PTJ5MUK=
MC-3  NH\QelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmSxOU8yOC9{MDFOwG0> MYSyOEBp MoC5SG1UVw>? M4S4[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVWyOlQ1PzZzNR?=
HN22  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS2cWkzNjVxNz61M|IzNjVizszN NYKxNoJ1OjRiaB?= M2DwbGROW09? MkHIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGjKSo0zPjR2N{[xOS=>
MC-3  NYjGeIpWSXCxcITvd4l{KEG|c3H5 Mn3DOU8yOC9{MDFOwG0> MYmyOEBp NUi2To1zTE2VTx?= NHLjcINqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MV[yOlQ1PzZzNR?=
HN22  MlnDRZBweHSxc3nzJGF{e2G7 NVX4WXBYOi53L{euOU8zOi53IN88US=> MY[yOEBp NHLjWmFFVVOR NV\rdItUcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NUK0boZ7OjZ2NEe2NVU>
MOLT-4 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNE02ODByIH7N M2XzelczKGh? MoXISG1UVw>? NUHQfVV4UUN3ME2wMlE6QCEQvF2= NGrN[|MzPjN7MkOzNi=>
RS4;11 M4XVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDRNVAuPTByMDDuUS=> NGHIOJY4OiCq NV:zdHZ5TE2VTx?= Mmi3TWM2OD1yLkCwNkDPxE1? MV[yOlM6OjN|Mh?=
JURKAT NYX5cZhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTMNVAuPTByMDDuUS=> MYS3NkBp NEDkcYpFVVOR MlHLTWM2OD14NjFOwG0> NF\JT2ozPjN7MkOzNi=>
CEM R NV\CPWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHjfWoyOC13MECwJI5O MYW3NkBp M2HSb2ROW09? MXjJR|UxRTVwNDFOwG0> Mo\vNlY{QTJ|M{K=
CEM S NV2zOFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LsUlExNTVyMECgcm0> MlnQO|IhcA>? NHW0SHJFVVOR NIrmZ5JKSzVyPUGyMlEh|ryP MUmyOlM6OjN|Mh?=
MOLT-4 NFSxcIRCeG:ydH;zbZMhSXO|YYm= MWSxNE0yODByIH7N M17kNVI1KGh? NVu5UJc1TE2VTx?= MnfGZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= NGrBeZYzPjN7MkOzNi=>
CEM S NV7ObGJUSXCxcITvd4l{KEG|c3H5 M2jJU|ExNTFyMECgcm0> NXnLN5lKOjRiaB?= M{PLdWROW09? M1\tWYNifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x M2HkOVI3Ozl{M{Oy
JURKAT M3PyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxNFAuOTByMDDuUS=> NVrYXZp6PDhiaB?= MXvEUXNQ NVfJWVlKUUN3ME25OVXDuTlwMzDuUS=> NEDmVWIzPjF5MkK2PS=>
LOUCY Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W4OFExOC1zMECwJI5O NI\qOVE1QCCq MkK3SG1UVw>? MUnJR|UxRTN{LklCtVExNjlibl2= NGrHTYQzPjF5MkK2PS=>
WM-115 NVv3bVNLS2WubDDWbYFjcWyrdImgRZN{[Xl? NVnMO41UOTBywrDuUS=> MlnjO|IhcA>? MkPU[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? MoXnNlYyOTZ5N{[=
B16 M1XieWNmdGxiVnnhZoltcXS7IFHzd4F6 NIHqZ3UyODEEoH7N NVjwSWR[PzJiaB?= MULlcohidmOnczDjeZJkfW2rbj3pcoR2[2WmIHHueIkue3W{dnn2ZYzDqA>? MXmyOlEyPjd5Nh?=
HL-60  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq3NkBp MW\JR|UxyqB;IEGwMlchdk1? M1zjTFI3ODR3NkC5
MOLM-13  NHfCeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp M3faN2lEPTEEoE2gNlcvQSCwTR?= M3:0VVI3ODR3NkC5
OCI-AML3 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrCcZk4OiCq MoTyTWM2OMLiPTCxPVUxKG6P MV:yOlA1PTZyOR?=
BCWM.1 M3PmSGFxd3C2b4Ppd{BCe3OjeR?= MmnYNE0yNjZizszN MYOyOEBp M{fpNYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3[xSVI2QDl|Mkmw
MWCL-1 MoexRZBweHSxc3nzJGF{e2G7 M1LZWVAuOS54IN88US=> NGT3S4MzPCCq M1i2c4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{L2NFI2QDl|Mkmw
MM.1s M{DEVGFxd3C2b4Ppd{BCe3OjeR?= MmGzNE0yNjZizszN NGfaPYozPCCq M2fs[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{jheVI2QDl|Mkmw
HCT116 M1;B[mZ2dmO2aX;uJGF{e2G7 MWGzM|ExKM7:TR?= NVvXVXlWOTMEoHlCpC=> NEjVNmFFVVOR M{\5O4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MmXKNlU4OTVyMki=
HCT116 BAX BAK1 DKO NUf6UGZKTnWwY4Tpc44hSXO|YYm= MnTyN{8yOCEQvF2= MmfLNVLDqGkEoB?= M3u5cmROW09? NW\mTVNycW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u NVr6V2ZOOjV5MUWwNlg>
HCT116 MVXGeY5kfGmxbjDBd5NigQ>? NVW4dlh4OTBizszN MYSxNuKhcMLi Ml6zSG1UVw>? NGfPV4NqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MV:yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NYC1UFdyTnWwY4Tpc44hSXO|YYm= NFvtUowyOCEQvF2= MnTQNVLDqGkEoB?= MkLhSG1UVw>? MX;pcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj NYPZU5FzOjV5MUWwNlg>
HCT116 NYX4XnFNSXW2b4DoZYd6KEG|c3H5 NGDr[YsyOCEQvF2= MYmxNuKhcMLi M3XwR2ROW09? Mn\MbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> MknONlU4OTVyMki=
HCT116 BAX BAK1 DKO MV;BeZRweGijZ4mgRZN{[Xl? NIfiU2MyOCEQvF2= NGTYSIcyOsLiaNMg M{WxOWROW09? NUWwcGdycW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNicnXzdI9ve2V? MV2yOVcyPTB{OB?=
U937 Mn;1RZBweHSxc3nzJGF{e2G7 NI\oZ2QxNjF{NT2yJO69VQ>? NHrsdnMzPCCq MX3lcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= NF7GNFEzPTdzNECyOC=>
U937  MkjoRZBweHSxc3nzJGF{e2G7 M1zYSVAvPSEQvF2= MXqyOEBp M2XzUYVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG|IF7vfIEhdGW4ZXy= MnLONlU4OTRyMkS=
HL-60 AAA-Bcl-2 MWTBdI9xfG:|aYOgRZN{[Xl? MVOwMVUh|ryP Mm\0OFghcA>? NH7kOnRKSzVyPUCuPFch|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXeyOVcyOTR4MB?=
HL-60 EEE-Bcl-2 NYHXV5dySXCxcITvd4l{KEG|c3H5 MVmwMVUh|ryP M4XTOlQ5KGh? M{C0U2lEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3jaVlI2PzFzNE[w
U87 M2iyUGZ2dmO2aX;uJGF{e2G7 NGH0OIE2OCEQvF2= MUeyOEBp NV;2UZdtemWmdXPld{B1cGVibWLORUBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUG0JIFv\CCEY3ytNi=> NYLjb|F2OjV4Nke2OlM>
K562 NXn2PIZKS2WubDDWbYFjcWyrdImgRZN{[Xl? NVrGTWRqOS1zMDFOwG0> NGG0XIw1QCCq MoHkSG1UVw>? M2faU2lEPTB;Mk[uO{DPxE1? NXfLVZJHOjV3OU[1OlE>
K562/Mcl -1-IRESBim MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTlwMzFOwG0> MoHuNlU2OzV7MEC=
K562/Bcl- 2-IRESBim NHSzU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDoTWM2OD1yLkO1JO69VQ>? NUfMOHRCOjV3M{W5NFA>
Jurkat NIrYN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nvXGlEPTB;MD62OkDPxE1? MkLINlU2OzV7MEC=
JurkatΔBak M3PwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzOmxKSzVyPkWwJO69VQ>? NUnOVm84OjV3M{W5NFA>
HL60/VCR MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRjFyMDFOwG0> M2jBN|I2PTN3OUCw
Kasumi-1 NI\VOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPUXINWUUN3ME2wMlAyKM7:TR?= MUiyOVU{PTlyMB?=
Kasumi-1/ABT M{PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DTSmlEPTB;MD61NUDPxE1? Mn3XNlU2OzV7MEC=
THP-1 NUDxfY9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwMkeg{txO NVHMR|NtOjV3M{W5NFA>
U937 NHvaZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwMkmg{txO M{P2[lI2PTN3OUCw
C1498 NFLXR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq4eYtKSzVyPU[uNVMh|ryP NILSfYczPTV|NUmwNC=>
RPMI 8226 MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWxNWZoUUN3ME2wMlI2KM7:TR?= NIPSN3kzPTV|NUmwNC=>
MM.1S Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwNECg{txO NYHJXG9ROjV3M{W5NFA>
NCI-H929 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PVbGlEPTB;MUWuNlEh|ryP NIH0eFUzPTV|NUmwNC=>
U266 M{HnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;vRlRnUUN3ME2wMlY5KM7:TR?= NYXNeFFrOjV3M{W5NFA>
MCF-7 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWrJSFFHPSEQvF2= MV60PEBp M1Xmb2ROW09? NWHyepV5\W6qYX7j[ZMhfGinIIPlcpNqfGm4aYT5JJRwKG:{IILh[IlifGmxbh?= MnztNlU1ODlzMkS=
MCF-7 MoTURZBweHSxc3nzJGF{e2G7 MY[1JO69VQ>? NGHNO3Y1NzJ2L{S4JIg> MojuSG1UVw>? NXntVZRJcW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA> M1fUWFI2PDB7MUK0
MCF-7 NVzBSmVWTnWwY4Tpc44hSXO|YYm= M{nodFUh|ryP NGm2ZWkzPCCq NVi0UWNlTE2VTx?= MlHh[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh M2nC[lI2PDB7MUK0
MDA-MB 231  M3HobmZ2dmO2aX;uJGF{e2G7 M1v2VVUh|ryP NEKzUZAzPCCq NHnNNmhFVVOR NGXyRYxmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? Mnr2NlU1ODlzMkS=
ZR-75-1  NYfa[np2TnWwY4Tpc44hSXO|YYm= NHq1cIc2KM7:TR?= MnPONlQhcA>? M{jkcmROW09? MnH2[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NIO5[IszPTRyOUGyOC=>
A549 M1G5[WNmdGxiVnnhZoltcXS7IFHzd4F6 MXuwMVIxKM7:TR?= M{PCZ|czKGh? NH;WdWhFVVOR MlH4[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M1vF[VI2Ozh6N{[y
H1299 NGezTmxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2Lo[FAuOjBizszN MXi3NkBp NUHhclZKTE2VTx?= NEDFZ5Nl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw NIqzTWQzPTN6OEe2Ni=>
HO-8910 MmSyR4VtdCCYaXHibYxqfHliQYPzZZk> NIPpSHUxNTJyIN88US=> M4\hRVczKGh? M{LGe2ROW09? NE[4Zoll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MVOyOVM5QDd4Mh?=
HT-29 NHXFV2lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEDrZWsxNTJyIN88US=> Mnn4O|IhcA>? NX34WmRwTE2VTx?= M13nXIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NVjOc2pQOjV|OEi3OlI>
HCT-116 Mm\lR4VtdCCYaXHibYxqfHliQYPzZZk> M4jneVAuOjBizszN MVS3NkBp MnHjSG1UVw>? NGL4bmhl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw M4\3UFI2Ozh6N{[y
A549 NYTEXFRsSXCxcITvd4l{KEG|c3H5 MYKyNEDPxE1? NVTzc5pYPDhiaB?= MVTEUXNQ Mmi0bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= MWCyOVM5QDd4Mh?=
H1299 M4HMNWFxd3C2b4Ppd{BCe3OjeR?= NHKySFYzOCEQvF2= MkTsOFghcA>? MUnEUXNQ NGPyPFJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> NFvCeWEzPTN6OEe2Ni=>
Sc-1 M1S2N2NmdGxiVnnhZoltcXS7IFHzd4F6 NEnLfWkxNjByMEGtNUDPxE1? MoLSPVYhcA>? Mlqw[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVzvd3hXOjV|N{O1NFg>
OcI-LY18 MoDHR4VtdCCYaXHibYxqfHliQYPzZZk> MVSwMlAxODFvMTFOwG0> MWi5OkBp M3PSdIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3\TZVI2Ozd|NUC4
RL  MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1LOSlAvODByMT2xJO69VQ>? MoLlPVYhcA>? MV;k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX7oeYlYOjV|N{O1NFg>
RKO M3Trc2NmdGxiVnnhZoltcXS7IFHzd4F6 MmDRNE0yOCEQvF2= NVG0dHB4OjUkgJnoxsA> M3WwXmROW09? NGHEflRKSzVyPvMAjVI26oDLwsXN M162UVI2OzB2M{iz
Caco-2 Mm\hR4VtdCCYaXHibYxqfHliQYPzZZk> M3\uOFAuOTBizszN NF\4R3YzPOLCiXlCpC=> NXvGT4g1TE2VTx?= NVTGc3UzUUN3ME2xPU446oDLwsXN MYKyOVMxPDN6Mx?=
DLD1 MnXUR4VtdCCYaXHibYxqfHliQYPzZZk> MYewMVExKM7:TR?= MlrBNlTjiImqwrC= M3LGeWROW09? NGjuT41KSzVyPUG4Mlc56oDLwsXN NVH6NplkOjV|MESzPFM>
LS411N MnTLR4VtdCCYaXHibYxqfHliQYPzZZk> M3r4e|AuOTBizszN MlraNlTjiImqwrC= MorPSG1UVw>? MXjJR|UxRTFzLkS35qCKyrWP MYSyOVMxPDN6Mx?=
SW620 MoH6R4VtdCCYaXHibYxqfHliQYPzZZk> NWO2[ohmOC1zMDFOwG0> NHLQ[I0zPOLCiXlCpC=> M3n6R2ROW09? M{D0eGlEPTB;MUKuNlTjiIoEtV2= MX:yOVMxPDN6Mx?=
HCT116 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGm5bogxNTFyIN88US=> NIT5[HczPOLCiXlCpC=> Mk\XSG1UVw>? MluwTWM2OD1{MD60PgKBkcL3TR?= M1PQ[FI2OzB2M{iz
HaCaT NV3RbFNmS2WubDDWbYFjcWyrdImgRZN{[Xl? NYi3e|IxOC5zL{GvNVAh|ryP M{\qNlI1KGh? NUT2dJA6TE2VTx?= MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWX3R49kOjV{MUC3PVU>
A5-RT3 NWTk[GFUS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml3aNE4yNzFxMUCg{txO M4\a[VI1KGh? M1r1ZWROW09? NELUdm9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYXvUWhyOjV{MUC3PVU>
HaCaT M4HF[GZ2dmO2aX;uJGF{e2G7 MkLBNVDjiIoQvF2= NGXpNogzPC92ODDo NInGXVNFVVOR NX7abmRlcW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u M1jHOlI2OjFyN{m1
A5-RT3 M{\ZcGZ2dmO2aX;uJGF{e2G7 NY\vZlBXOTEkgJpOwG0> MYiyOE81QCCq MWHEUXNQ NXrsXnU{cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u M3;U[FI2OjFyN{m1
A5-RT3 M4nVPWZ2dmO2aX;uJGF{e2G7 M{\yOFUh|ryP MnPMOkBp NWnQe25mTE2VTx?= MkTzbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=> MVWyOVIyODd7NR?=
U266 MoPqSpVv[3Srb36gRZN{[Xl? MWm1NFAwPzVyIH7N MUmyOE81QCCq MojRSG1UVw>? NGDmSXNld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M3LM[VI2OjB6OEi4
RPMI8226 M3zWUWZ2dmO2aX;uJGF{e2G7 MWO1NFAwPzVyIH7N NWHMNFFOOjRxNEigbC=> NWi5ZWlETE2VTx?= M{PUUIRwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> NHXhVGMzPTJyOEi4PC=>
MM.1S MYDGeY5kfGmxbjDBd5NigQ>? MW[1NFAwPzVyIH7N MVSyOE81QCCq NFviPHdFVVOR Ml;o[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NEKwOIgzPTJyOEi4PC=>
Clone A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;ENE4z6oDVNkCg{txO NV\RNIZpPzJiaB?= M1PTVmROW09? Mmi2TWM2OD15LkWg{txO M2rJW|I2OjB6OEiy
CX-1 NITpTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ixRVAvOuLCk{[wJO69VQ>? M33DZ|czKGh? NYjYUoVuTE2VTx?= NULvdHdjUUN3ME2xMlgh|ryP MVqyOVIxQDh6Mh?=
LS174T NF\aOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fnUFAvOuLCk{[wJO69VQ>? MmP3O|IhcA>? M3;5cmROW09? NXzZ[FBTUUN3ME2xPE4{KM7:TR?= M{DZcFI2OjB6OEiy
HT29 MlT2RZBweHSxc3nzJGF{e2G7 MkHPNU82NzFyIN88US=> NITKTJo1QCCq M{ntc4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mk\ZNlUyQTJzOEi=
SW480 NHLpSYJCeG:ydH;zbZMhSXO|YYm= M3XXdVEwPS9zMDFOwG0> MkjzOFghcA>? NV7KVGh[[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mn3LNlUyQTJzOEi=
Colo205 MlTKRZBweHSxc3nzJGF{e2G7 Mle0NU82NzFyIN88US=> NXK1V|V7PDhiaB?= MUXjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWfVXI85OjVzOUKxPFg>
Caco2 MVTBdI9xfG:|aYOgRZN{[Xl? MVOxM|UwOTBizszN NVrGUHhLPDhiaB?= MX3jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NG\K[24zPTF7MkG4PC=>
PCI-13 NEPD[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO3NkBp NHLWV4NFVVOR NF\4RXRIUTVyPUG1JOKyKDFwODFOwG0> MYWyOVE{QTN6Nx?=
PCI-15B MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[1TmhFPzJiaB?= NUHxdXZ[TE2VTx?= Ml;0S2k2OD1zMTFCtUA1NjVizszN NEHEdokzPTF|OUO4Oy=>
UM-SCC22B NV[4PIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS3NkBp MU\EUXNQ MkfpS2k2OD1zOTFCtUAzNjlizszN NYr2U3Y{OjVzM{mzPFc>
UM-SCC47 M2rDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\UO|IhcA>? NEDJNFRFVVOR MVLHTVUxRTF7INMxJFEzNjNizszN NYW0VIlvOjVzM{mzPFc>
93-VU-147T NHP1NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq3NkBp M2C3e2ROW09? M{j1W2dKPTB;ND6zJOKyKDNwNTFOwG0> M{Wz[lI2OTN7M{i3
UD-SCC2 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P6V|czKGh? NFzhXnFFVVOR M2fpd2dKPTB;MkigxtEhOi57IN88US=> MXGyOVE{QTN6Nx?=
UPCI:SCC90 M2DxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnIT5g4OiCq NVLO[ppoTE2VTx?= NVW0VYd6T0l3ME22MlYhyrFiMT61JO69VQ>? Mlu5NlUyOzl|OEe=
RPMI-8226  NVrQPYw5S2WubDDWbYFjcWyrdImgRZN{[Xl? MVixNlUwOjVyL{WwNEBvVQ>? MoixOFhpyqB? M3\oWWROW09? M3PNbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWKyOVAxQDJyMh?=
OPM-2  MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFX0SIkyOjVxMkWwM|UxOCCwTR?= M3jncVQ5cMLi MXTEUXNQ M13TXIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHnWT4EzPTByOEKwNi=>
RPMI-8226  MVjBdI9xfG:|aYOgRZN{[Xl? Mn7UNVI2NzJ3MD:1NFAhdk1? MoXIOFhpyqB? MnHiSG1UVw>? NFfvcI9qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2fCcFI2ODB6MkCy
OPM-2  MorwRZBweHSxc3nzJGF{e2G7 MUexNlUwOjVyL{WwNEBvVQ>? MnPoOFhpyqB? MlPESG1UVw>? MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEPldJkzPTByOEKwNi=>
COG-LL-319 M2m4PGZ2dmO2aX;uJGF{e2G7 MnzzNVAxKG6P NF71WJUyNzNxNjDo M1\xNGROW09? NWf5c4l[cW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= MUSyOFk2OTR5Mh?=
RS4;11 NVzNfFc3TnWwY4Tpc44hSXO|YYm= MlmwNVAxKG6P NXH1UpBYOS9|L{[gbC=> M2fuRWROW09? MVnpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm MYKyOFk2OTR5Mh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / c-PARP / cleaved caspase 3 ; 

PubMed: 21393866     


H146 cells were preincubated in normoxia or hypoxia (1% O2) for 18 hours prior to treatment with ABT-737 (89.1 nM ), after which cells were harvested for protein analysis by Western blot. 

Hif-1a; 

PubMed: 22006676     


Representative western blots for HIF-1α, PARP and cleaved caspase 3 in response to 24-72 hr exposure to ABT-737 in varying concentration in normoxia and hypoxia in 4 neuroblastoma cell lines. Actin is shown as a loading control. Blots are representative of 3 independent experiments.

γ-H2AX / p-ATM; 

PubMed: 21084274     


Induction of γ-H2AX and p-ATM by ABT-737. Cells were treated with 10 µmol/L ABT-737 for 24 hours and then maintained in fresh media for 1 or 2 more days prior to Western blot analysis.

21393866 22006676 21084274
Immunofluorescence
cytochrome C; 

PubMed: 26447615     


Immunocytochemistry revealed the release of mitochondrial cytochrome c (green) into the cytoplasm after ABT-737 exposure (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

Bax; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bax from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field C. To assess whether ABT-737 treatment has an effect on the dimerization of Bax, the levels of dimeric Bax were measured with or without ABT-737 treatment in MC-3 and HN22 cells.

Bim; 

PubMed: 26447615     


Immunocytochemistry revealed the mitochondrial translocation of Bim from the cytoplasm after ABT-737 treatment (20 μM in MC-3 cells and 22.5 μM in HN22 cells) for 24 hr. MitoTracker (red) staining labels mitochondria within each field.

AIF; 

PubMed: 25034785     


localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification × 60, zoom × 3, bar 20 μm. 

p65 ; 

PubMed: 28846096     


BCL-xL dependent SVEC cells were treated with ABT-737 (10 μM) +/- Q-VD-Oph (30 μM) for 1 h, immunostained for p65 and analysed by confocal microscopy. TNF (20 ng/ml) was used as positive control for p65 nuclear translocation. Scale bar represents 30μM. Representative images from three independent experiments.

26447615 25034785 28846096
Growth inhibition assay
Cell viability; 

PubMed: 22311987     


Stably transfected K562 cells were treated with increasing concentrations of ABT-737, obatoclax, or maritoclax for 24 h. Cell viability was determined by measuring intracellular ATP levels with the CellTiter Glo assay.

22311987
ELISA
IL-6 / IL-8; 

PubMed: 21084274     


The secretion of IL-6 and IL-8 in PV-10 cells treated with DMSO, ABT-737 or enantiomer for 24 hours was determined by ELISA.

21084274
In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

- Collapse

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

- Collapse
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID